Identification
- Summary
Ropinirole is a non-ergoline dopamine agonist used to treat the symptoms of Parkinson's disease and Restless Legs Syndrome.
- Brand Names
- Requip
- Generic Name
- Ropinirole
- DrugBank Accession Number
- DB00268
- Background
Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome Label, 3. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA Label for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome 3.
In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole 4.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Ropinirole (DB00268)
- Weight
- Average: 260.3746
Monoisotopic: 260.1888634 - Chemical Formula
- C16H24N2O
- Synonyms
- Ropinirol
- Ropinirole
- Ropinirolum
- External IDs
- SK&F 101468
- SK&F-101468
Pharmacology
- Indication
For the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome Label.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Parkinson disease, idiopathic •••••••••••• •••••••• •••••••• ••••••• Management of Parkinson's disease •••••••••••• •••••• Used in combination for symptomatic treatment of Parkinson's disease Regimen in combination with: Levodopa (DB01235) ••• ••••• Treatment of Moderate restless legs syndrome •••••••••••• •••••• Treatment of Severe restless legs syndrome •••••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Effects on Parkinson's and restless leg syndrome
This drug promotes the relief or improvement of symptoms of Parkinson's or restless leg syndrome by stimulatory actions on dopamine receptors, which regulate movement.
Effects on blood pressure
Clinical experience with dopamine agonists, including ropinirole, suggests an association with impaired abilities in regulating blood pressure with resulting orthostatic hypotension, especially with patients undergoing dose escalation. In some patients in clinical studies, blood pressure changes were associated with orthostatic symptoms, bradycardia, and, in one case in a healthy volunteer, transient sinus arrest accompanied by syncope Label. The mechanism of orthostatic hypotension caused by ropinirole is assumed to be due to a D2-mediated blunting of noradrenergic response to a standing position, followed by a decrease in peripheral vascular resistance. Nausea is also a frequent symptom which accompanies orthostatic signs and symptoms Label.
Effects on prolactin
At oral doses as low as 0.2 mg, ropinirole suppressed serum prolactin concentrations in healthy male volunteers. Ropinirole had no dose-related effect on ECG wave form and rhythm in young, healthy, male volunteers in the range of 0.01 to 2.5 mg Label.
Effects on QT interval
Ropinirole had no dose- or exposure-related effect on average QT intervals in healthy male and female volunteers at doses up to 4 mg/day. The effect of ropinirole on QTc intervals at higher exposures reached either due to drug interactions, hepatic dysfunction, or at higher doses has not been adequately evaluated Label.
- Mechanism of action
Ropinirole is a non-ergoline dopamine agonist. Ropinirole has the highest affinity at the D3 receptors, which are concentrated in the limbic areas of the brain and may be responsible for some of the neuropsychiatric effects 4. The exact mechanism of action of ropinirole as a treatment for Parkinson’s disease is unknown, however, it is believed to be related to its ability to selectively stimulate dopamine D2 receptors within the caudate-putamen system in the brain. This system affects body movement. Negligible affinity is seen for ropinirole at α2 adrenoreceptors in the periphery and 5HT-1 receptor. Ropinirole has no affinity at the D1-like receptors, benzodiazepine or GABA receptors 4.
The precise mechanism of action of ropinirole as a treatment for Restless Legs Syndrome is unknown, however, it is believed to be related to its ability to stimulate dopamine receptors Label.
Target Actions Organism ADopamine D3 receptor agonistHumans ADopamine D2 receptor agonistHumans UDopamine D4 receptor agonistHumans UAlpha adrenergic receptor antagonistHumans - Absorption
Ropinirole is rapidly absorbed after oral administration, reaching peak concentration in approximately 1 to 2 hours Label, 5.
Absolute bioavailability was 45% to 55%, suggesting approximately 50% hepatic first-pass effect Label. The bioavailability of ropinirole prolonged release compared to the immediate release tablets is about 100% 2.
Ingestion of food does not affect the absorption of ropinirole, although its Tmax was increased by 2.5 hours and its Cmax was reduced by approximately 25% when the drug is taken with a high-fat meal Label.
- Volume of distribution
Ropinirole is found to be widely distributed throughout the body, with an apparent volume of distribution of 7.5 L/kg Label.
- Protein binding
40% bound to plasma proteins with a blood-to-plasma ratio of 1:1 Label.
- Metabolism
Ropinirole is heavily metabolized by the liver. The most important metabolic pathways are N despropylation and hydroxylation to form the N-despropyl metabolite and hydroxy metabolites Label, both of which are inactive 4.
The N-despropyl metabolite is then converted to carbamyl glucuronide, carboxylic acid, and N-despropyl hydroxy metabolites. Following this process, the hydroxy metabolite of ropinirole is glucuronidated at a rapid rate Label.
In vitro studies show that the major cytochrome P450 enzyme involved in the metabolism of ropinirole is CYP1A2 Label, 5.
Hover over products below to view reaction partners
- Route of elimination
The majority of the absorbed dose is cleared by the liver 4.
In clinical trials, more than 88% of a radiolabeled dose was recovered in urine Label. Less than 10% of the administered dose is excreted as unchanged drug in urine. N-despropyl ropinirole is the major metabolite found in the urine (40%), followed by the carboxylic acid metabolite (10%), and the glucuronide of the hydroxy metabolite (10%) Label.
- Half-life
- Clearance
The clearance of ropinirole after oral administration is 47 L/h Label.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Overdose
Symptoms of overdose include agitation, chest pain, confusion, drowsiness, facial muscle movements, grogginess, increased jerkiness of movement, symptoms of low blood pressure (dizziness, light-headedness)upon standing, nausea, and vomiting Label.
Carcinogenicity
Two-year carcinogenicity studies of ropinirole were performed on animal models at oral doses of 5, 15, and 50 mg/kg/day and in rats at oral doses of 1.5, 15, and 50 mg/kg/day. There was an increase in testicular Leydig cell adenomas at all doses tested in rats. The hormonal mechanisms thought to be involved in the development of these tumors in rats are not considered relevant to humans. In mice, there was an increase in benign uterine endometrial polyps at a dose of 50 mg/kg/day. The highest dose not associated with this observation (15 mg/kg/day) is three times the maximum recommended human dose on a mg/m2 basis Label.
Mutagenesis
Ropinirole was not found to be mutagenic or clastogenic during in vitro assays, or in the in vivo mouse micronucleus test Label.
Effects on reproduction
When given to female rats prior to and during mating and throughout pregnancy, ropinirole led to disruption of implantation at oral doses of 20 mg/kg/day (8 times the MRHD on a mg/m2 basis) or higher. This effect in rats is believed to be due to the prolactin-lowering effects of ropinirole.
Use in Pregnancy
Pregnancy Category C. There are no sufficient and well-controlled studies done in pregnant women. In animal reproduction studies, ropinirole has demonstrated adverse effects on embryo-fetal development, including teratogenicity Label.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine 1,2-Benzodiazepine may increase the sedative activities of Ropinirole. Abaloparatide The risk or severity of adverse effects can be increased when Ropinirole is combined with Abaloparatide. Abametapir The serum concentration of Ropinirole can be increased when it is combined with Abametapir. Abatacept The metabolism of Ropinirole can be increased when combined with Abatacept. Abiraterone The serum concentration of Ropinirole can be increased when it is combined with Abiraterone. - Food Interactions
- Take with or without food. May take with food to reduce nausea.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Ropinirole Hydrochloride D7ZD41RZI9 91374-20-8 XDXHAEQXIBQUEZ-UHFFFAOYSA-N - Product Images
- International/Other Brands
- Adartrel / ReQuip CR (GlaxoSmithKline) / Ronirol
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Requip Tablet, film coated 3 mg/1 Oral Physicians Total Care, Inc. 2006-02-20 2008-12-31 US 
Requip Tablet, film coated 1 mg/1 Oral Pd Rx Pharmaceuticals, Inc. 1997-10-01 2018-04-27 US 
Requip Tablet, film coated 0.5 mg/1 Oral Physicians Total Care, Inc. 2007-02-27 2008-12-31 US Requip Tablet, film coated 3 mg/1 Oral Glaxo Wellcome SA 2001-06-19 2018-10-31 US Requip Tablet, film coated 4 mg/1 Oral GlaxoSmithKline LLC 1999-09-21 2019-11-30 US 
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Apo-ropinirole Tablet 3.0 mg Oral Apotex Corporation Not applicable Not applicable Canada 
Apo-ropinirole Tablet 0.5 mg Oral Apotex Corporation Not applicable Not applicable Canada Apo-ropinirole Tablet 5.0 mg Oral Apotex Corporation Not applicable Not applicable Canada Apo-ropinirole Tablet 2.0 mg Oral Apotex Corporation Not applicable Not applicable Canada Apo-ropinirole Tablet 0.25 mg Oral Apotex Corporation Not applicable Not applicable Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Requip Ropinirole Hydrochloride + Ropinirole Hydrochloride + Ropinirole Hydrochloride Tablet, film coated Oral GlaxoSmithKline 2006-10-06 2006-10-06 US Requip Ropinirole Hydrochloride + Ropinirole Hydrochloride + Ropinirole Hydrochloride Tablet, film coated Oral GlaxoSmithKline 2006-10-06 2006-10-06 US Requip Ropinirole Hydrochloride + Ropinirole Hydrochloride + Ropinirole Hydrochloride Tablet, film coated Oral GlaxoSmithKline 2006-10-06 2006-10-06 US
Categories
- ATC Codes
- N04BC04 — Ropinirole
- Drug Categories
- Anti-Dyskinesia Agents
- Anti-Parkinson Agents (Dopamine Agonist)
- Anti-Parkinson Drugs
- Central Nervous System Agents
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 Substrates
- Dopamine Agents
- Dopamine Agonists
- Heterocyclic Compounds, Fused-Ring
- Hypotensive Agents
- Nervous System
- Neurotransmitter Agents
- Nonergot-derivative Dopamine Receptor Agonists
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as indolines. These are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2,3-dihydroindole.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Indoles and derivatives
- Sub Class
- Indolines
- Direct Parent
- Indolines
- Alternative Parents
- Phenethylamines / Aralkylamines / Trialkylamines / Secondary carboxylic acid amides / Lactams / Amino acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives show 1 more
- Substituents
- Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Dihydroindole show 12 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- tertiary amine, indolones (CHEBI:8888)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 030PYR8953
- CAS number
- 91374-21-9
- InChI Key
- UHSKFQJFRQCDBE-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)
- IUPAC Name
- 4-[2-(dipropylamino)ethyl]-2,3-dihydro-1H-indol-2-one
- SMILES
- CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
References
- Synthesis Reference
- US4452808
- General References
- Matheson AJ, Spencer CM: Ropinirole: a review of its use in the management of Parkinson's disease. Drugs. 2000 Jul;60(1):115-37. doi: 10.2165/00003495-200060010-00007. [Article]
- Nashatizadeh MM, Lyons KE, Pahwa R: A review of ropinirole prolonged release in Parkinson's disease. Clin Interv Aging. 2009;4:179-86. Epub 2009 May 14. [Article]
- Kushida CA: Ropinirole for the treatment of restless legs syndrome. Neuropsychiatr Dis Treat. 2006 Dec;2(4):407-19. [Article]
- Shill HA, Stacy M: Update on ropinirole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:33-6. Epub 2009 Apr 8. [Article]
- Kaye CM, Nicholls B: Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000 Oct;39(4):243-54. doi: 10.2165/00003088-200039040-00001. [Article]
- Drug Approval Package, FDA [Link]
- FDA Approved Drug Products: Requip (ropinirole) tablets for oral use [Link]
- FDA Approved Drug Products: Requip XL (ropinirole) extended-release tablets for oral use [Link]
- Ropinirole extended release FDA label [File]
- UK labeling, Ropinirole [File]
- External Links
- Human Metabolome Database
- HMDB0014413
- KEGG Drug
- D08489
- KEGG Compound
- C07564
- PubChem Compound
- 5095
- PubChem Substance
- 46507918
- ChemSpider
- 4916
- BindingDB
- 50020680
- 72302
- ChEBI
- 8888
- ChEMBL
- CHEMBL589
- ZINC
- ZINC000000002041
- Therapeutic Targets Database
- DAP001515
- PharmGKB
- PA164749035
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Ropinirole
- FDA label
- Download (796 KB)
- MSDS
- Download (29.6 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Diagnostic Parkinson's Disease (PD) 1 4 Completed Supportive Care Cirrhosis of the Liver / Muscle Cramps 1 4 Completed Treatment Bipolar Disorder (BD) 1 4 Completed Treatment Parkinson's Disease (PD) 4 4 Completed Treatment Restless Legs Syndrome (RLS) 2
Pharmacoeconomics
- Manufacturers
- Smithkline beecham corp dba glaxosmithkline
- Glaxosmithkline
- Alembic ltd
- Corepharma llc
- Glenmark generics ltd
- Huahai us inc
- Mylan pharmaceuticals inc
- Roxane laboratories inc
- Teva pharmaceuticals usa inc
- Wockhardt ltd
- Zydus pharmaceuticals usa inc
- Packagers
- Amerisource Health Services Corp.
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- Bryant Ranch Prepack
- Cadila Healthcare Ltd.
- Cardinal Health
- Corepharma LLC
- GlaxoSmithKline Inc.
- Glenmark Generics Ltd.
- Heartland Repack Services LLC
- Heritage Pharmaceuticals
- Innoviant Pharmacy Inc.
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Major Pharmaceuticals
- Mckesson Corp.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Nucare Pharmaceuticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Rebel Distributors Corp.
- Resource Optimization and Innovation LLC
- Roxane Labs
- Stat Rx Usa
- Teva Pharmaceutical Industries Ltd.
- Vangard Labs Inc.
- Wockhardt Ltd.
- Zydus Pharmaceuticals
- Dosage Forms
Form Route Strength Tablet, film coated Oral Tablet, film coated Oral 0.25 MG Tablet, film coated Oral 0.5 MG Tablet, film coated Oral 2 MG Tablet Oral 3.0 mg Tablet Oral 4.0 mg Tablet Oral Tablet Oral 9.120 mg Tablet Oral 0.25 mg Tablet Oral 0.5 mg Tablet Oral 1.0 mg Tablet Oral 2.0 mg Tablet Oral 5.0 mg Tablet, film coated Oral Tablet, film coated Oral 0.25 mg/1 Tablet, film coated Oral 0.5 mg/1 Tablet, film coated Oral 1 mg/1 Tablet, film coated Oral 2 mg/1 Tablet, film coated Oral 3 mg/1 Tablet, film coated Oral 4 mg/1 Tablet, film coated Oral 1.0 MG Tablet, film coated Oral 2.0 MG Tablet, film coated Oral 5.0 MG Tablet, extended release Oral Tablet, film coated, extended release Oral 2 mg Tablet, film coated, extended release Oral 4 mg Tablet, film coated Oral 1 mg Tablet, film coated, extended release Oral 2 mg/1 Tablet, film coated Oral 5 MG Tablet, film coated Oral 3 MG Tablet, film coated Oral 4 MG Tablet, extended release Oral 3 MG Tablet Oral 4 mg/1 Tablet, extended release Oral 12 mg/1 Tablet, extended release Oral 2 mg/1 Tablet, extended release Oral 4 mg/1 Tablet, extended release Oral 6 mg/1 Tablet, extended release Oral 8 mg/1 Tablet Oral 0.25 mg/1 Tablet Oral 0.5 mg/1 Tablet Oral 1 mg/1 Tablet Oral 2 mg/1 Tablet Oral 3 mg/1 Tablet Oral 5 mg/1 Tablet, coated Oral 0.25 mg/1 Tablet, coated Oral 0.5 mg/1 Tablet, coated Oral 1 mg/1 Tablet, coated Oral 2 mg/1 Tablet, coated Oral 3 mg/1 Tablet, coated Oral 4 mg/1 Tablet, coated Oral 5 mg/1 Tablet, film coated Oral 5 mg/1 Tablet, film coated, extended release Oral 12 mg/1 Tablet, film coated, extended release Oral 3 mg/1 Tablet, film coated, extended release Oral 4 mg/1 Tablet, film coated, extended release Oral 6 mg/1 Tablet, film coated, extended release Oral 8 mg/1 Tablet Oral 1 mg Tablet Oral 2 mg Tablet Oral 5 mg Tablet, extended release Oral 2 mg Tablet, extended release Oral 8 mg Tablet, extended release Oral 4 mg - Prices
Unit description Cost Unit Requip XL 12 mg 24 Hour tablet 14.92USD tablet Requip xl 12 mg tablet 14.35USD tablet Requip XL 8 mg 24 Hour tablet 8.96USD tablet Requip xl 6 mg tablet 8.61USD tablet Requip xl 8 mg tablet 8.61USD tablet Requip XL 4 mg 24 Hour tablet 5.97USD tablet Requip xl 4 mg tablet 5.74USD tablet Requip 5 mg Tablet 3.87USD tablet Requip 3 mg tablet 3.41USD tablet Requip 4 mg tablet 3.41USD tablet Requip 5 mg tablet 3.41USD tablet Requip 0.25 mg tablet 3.29USD tablet Requip 0.5 mg tablet 3.29USD tablet Requip 1 mg tablet 3.29USD tablet Requip 2 mg tablet 3.29USD tablet Requip xl 2 mg tablet 2.87USD tablet Ropinirole hcl 3 mg tablet 2.65USD tablet Ropinirole hcl 4 mg tablet 2.65USD tablet Ropinirole hcl 5 mg tablet 2.65USD tablet Ropinirole hcl 0.25 mg tablet 2.55USD tablet Ropinirole hcl 0.5 mg tablet 2.55USD tablet Ropinirole hcl 1 mg tablet 2.55USD tablet Ropinirole hcl 2 mg tablet 2.55USD tablet Co Ropinirole 5 mg Tablet 1.8USD tablet Pms-Ropinirole 5 mg Tablet 1.8USD tablet Ran-Ropinirole 5 mg Tablet 1.8USD tablet Ropinirole 5 mg Tablet 1.8USD tablet Requip 2 mg Tablet 1.41USD tablet Requip 1 mg Tablet 1.28USD tablet Co Ropinirole 2 mg Tablet 0.65USD tablet Pms-Ropinirole 2 mg Tablet 0.65USD tablet Ran-Ropinirole 2 mg Tablet 0.65USD tablet Ropinirole 2 mg Tablet 0.65USD tablet Co Ropinirole 1 mg Tablet 0.59USD tablet Pms-Ropinirole 1 mg Tablet 0.59USD tablet Ran-Ropinirole 1 mg Tablet 0.59USD tablet Ropinirole 1 mg Tablet 0.59USD tablet Requip 0.25 mg Tablet 0.32USD tablet Co Ropinirole 0.25 mg Tablet 0.15USD tablet Pms-Ropinirole 0.25 mg Tablet 0.15USD tablet Ran-Ropinirole 0.25 mg Tablet 0.15USD tablet Ropinirole 0.25 mg Tablet 0.15USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5422123 No 1995-06-06 2012-06-06 US US7927624 No 2011-04-19 2021-12-02 US US8303986 No 2012-11-06 2021-04-12 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 243-250 °C FDA label boiling point (°C) 410.5±45.0 °C at 760 mmHg http://www.chemspider.com/Chemical-Structure.4916.html water solubility 133 mg/mL FDA label logP 3.06 http://www.t3db.ca/toxins/T3D2731 logS -2.9 http://www.t3db.ca/toxins/T3D2731 pKa 10.17 http://www.t3db.ca/toxins/T3D2731 - Predicted Properties
Property Value Source Water Solubility 0.353 mg/mL ALOGPS logP 3.16 ALOGPS logP 3.06 Chemaxon logS -2.9 ALOGPS pKa (Strongest Acidic) 12.27 Chemaxon pKa (Strongest Basic) 10.17 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 32.34 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 81.43 m3·mol-1 Chemaxon Polarizability 31.19 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9971 Caco-2 permeable + 0.6087 P-glycoprotein substrate Substrate 0.7604 P-glycoprotein inhibitor I Inhibitor 0.5458 P-glycoprotein inhibitor II Non-inhibitor 0.8641 Renal organic cation transporter Non-inhibitor 0.602 CYP450 2C9 substrate Non-substrate 0.8593 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Substrate 0.6903 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Inhibitor 0.8932 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8309 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6959 Ames test Non AMES toxic 0.7302 Carcinogenicity Non-carcinogens 0.905 Biodegradation Not ready biodegradable 0.9966 Rat acute toxicity 2.6400 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8959 hERG inhibition (predictor II) Non-inhibitor 0.7066
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-03kd-8950000000-65ad14635cd7e9f25153 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0290000000-7b641434909a40f235b0 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-0090000000-17c59746691082152a74 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-4970000000-4889c117fc9a345fb830 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-0390000000-656de9da5c17377b8c51 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00ls-3930000000-621e41c0879ecc6862cb Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-0910000000-81ae01aba6581c8739ca Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 173.1865505 predictedDarkChem Lite v0.1.0 [M-H]- 172.6297505 predictedDarkChem Lite v0.1.0 [M-H]- 177.0630505 predictedDarkChem Lite v0.1.0 [M-H]- 161.51833 predictedDeepCCS 1.0 (2019) [M+H]+ 173.4277505 predictedDarkChem Lite v0.1.0 [M+H]+ 172.4317505 predictedDarkChem Lite v0.1.0 [M+H]+ 177.0203505 predictedDarkChem Lite v0.1.0 [M+H]+ 163.87633 predictedDeepCCS 1.0 (2019) [M+Na]+ 173.6750505 predictedDarkChem Lite v0.1.0 [M+Na]+ 172.7797505 predictedDarkChem Lite v0.1.0 [M+Na]+ 169.96947 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- G-protein coupled amine receptor activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
- Gene Name
- DRD3
- Uniprot ID
- P35462
- Uniprot Name
- D(3) dopamine receptor
- Molecular Weight
- 44224.335 Da
References
- Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [Article]
- Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [Article]
- Nashatizadeh MM, Lyons KE, Pahwa R: A review of ropinirole prolonged release in Parkinson's disease. Clin Interv Aging. 2009;4:179-86. Epub 2009 May 14. [Article]
- Shill HA, Stacy M: Update on ropinirole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:33-6. Epub 2009 Apr 8. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Potassium channel regulator activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
References
- de Mey C, Enterling D, Meineke I, Yeulet S: Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist. Br J Clin Pharmacol. 1991 Oct;32(4):483-8. [Article]
- Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N: Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 1999 Aug 14;838(1-2):51-9. [Article]
- Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [Article]
- Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [Article]
- Matsukawa N, Maki M, Yasuhara T, Hara K, Yu G, Xu L, Kim KM, Morgan JC, Sethi KD, Borlongan CV: Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. Brain Res. 2007 Jul 30;1160:113-23. Epub 2007 May 26. [Article]
- Shill HA, Stacy M: Update on ropinirole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:33-6. Epub 2009 Apr 8. [Article]
- Requip FDA label [File]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Sh3 domain binding
- Specific Function
- Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
- Gene Name
- DRD4
- Uniprot ID
- P21917
- Uniprot Name
- D(4) dopamine receptor
- Molecular Weight
- 48359.86 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [Article]
- Shill HA, Stacy M: Update on ropinirole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:33-6. Epub 2009 Apr 8. [Article]
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Components:
References
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [Article]
- Wynalda MA, Wienkers LC: Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos. 1997 Oct;25(10):1211-4. [Article]
- Kaye CM, Nicholls B: Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000 Oct;39(4):243-54. doi: 10.2165/00003088-200039040-00001. [Article]
- Kushida CA: Ropinirole for the treatment of restless legs syndrome. Neuropsychiatr Dis Treat. 2006 Dec;2(4):407-19. [Article]
- Ropinrole FDA label [File]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55